12/4
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
12/1
08:11 am
mdgl
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug [Yahoo! Finance]
11/21
11:27 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $568.00 to $620.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $568.00 to $620.00. They now have a "buy" rating on the stock.
11/20
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
11/20
08:07 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $600.00 to $650.00. They now have an "outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $600.00 to $650.00. They now have an "outperform" rating on the stock.
11/19
12:59 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Truist Financial Corporation from $580.00 to $640.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Truist Financial Corporation from $580.00 to $640.00. They now have a "buy" rating on the stock.
11/18
10:42 pm
mdgl
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis [Yahoo! Finance]
11/17
08:12 am
mdgl
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences [Yahoo! Finance]
11/17
08:00 am
mdgl
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Medium
Report
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
11/13
04:04 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $526.00 to $587.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $526.00 to $587.00. They now have a "buy" rating on the stock.
11/11
11:42 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $500.00 to $568.00. They now have a "buy" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $500.00 to $568.00. They now have a "buy" rating on the stock.
11/10
08:40 am
mdgl
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis [Yahoo! Finance]
Low
Report
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis [Yahoo! Finance]
11/10
08:00 am
mdgl
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Low
Report
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
11/6
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
11/5
08:10 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $527.00 price target on by analysts at JMP Securities.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $527.00 price target on by analysts at JMP Securities.
11/5
08:07 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $485.00 to $527.00. They now have a "market outperform" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $485.00 to $527.00. They now have a "market outperform" rating on the stock.
11/5
07:19 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/4
06:02 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
11/4
07:00 am
mdgl
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Medium
Report
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
11/3
08:03 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $445.00 price target on the stock, up previously from $266.00.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $445.00 price target on the stock, up previously from $266.00.
10/28
08:00 am
mdgl
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Medium
Report
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
10/22
08:00 am
mdgl
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
Medium
Report
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
10/21
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
10/15
08:03 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $540.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $540.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
10/14
06:08 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $580.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $580.00 price target on by analysts at Truist Financial Corporation.